Ann: Nuheara Receives US FDA Approval and Launches HP Hearing PRO, page-140

it’s true Nuheara hasn’t previously had a cashflow positive period, and I agree a CR is a possibility, but speculation all the same.

It was not a fantasy that recent interest pushed the price up to 35… and its largely healthcare2030 selling that has brought it back down.

And as for the viability of OTC hearing aids… I don’t think it is fair to use Nuheara’s cashflow history pre FDA approval as an indicator or any future cashflow which may come now FDA approval has been granted.